Impact of Metabolite Supplementation to Restore Mitochondrial Dysfunction During Septic Shock: a Preclinical Study

Launched by UNIVERSITY HOSPITAL, ANGERS · Feb 27, 2020

Keywords

ClinConnect Summary

This clinical trial is studying how certain substances, called metabolites, can help improve the function of tiny energy-producing parts of our cells, known as mitochondria, in patients experiencing septic shock. Septic shock is a serious condition that occurs when an infection leads to dangerously low blood pressure and can cause multiple organs to fail. The trial aims to see if giving these metabolites can help restore normal cell function and reduce complications related to a build-up of lactic acid, which happens during septic shock.

To be eligible for this study, patients must be 18 years or older, diagnosed with septic shock according to specific medical criteria, and admitted to the intensive care unit at Angers University Hospital. Participants will have their health closely monitored, and researchers will collect information about their medical history and treatment outcomes for up to 28 days. Additionally, they will test whether adding these metabolites in a lab setting can improve cell function. This study is currently recruiting participants, and anyone interested should discuss it with their healthcare provider.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All patients aged 18 or more
• • Patients with criteria for septic shock according to SEPSIS 3 definition (presumed sepsis, with persisting hypotension requiring vasopressors to maintain mean arterial pressure \> 65 mmHg and having a serum lactate \> 2 mmol/L despite adequate fluid expansion).
• • Admitted in the ICU of Angers University Hospital
• Exclusion Criteria:
• • Minor patients (aged less 18)
• • Patient subject to legal protection measures
• • Refusal of the patient or his family
• • Preexisting mitochondrial disease
• • Patient with aplasia
• • Pregnant or parturient women